Nanomerics - Pharmaceutical Nanotechnology

“Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current medicines and develop products that deliver patient benefit in areas of unmet medical need.”

Nanomerics CEO at Expert Meeting at Houses of Parliament

On April 17th Nanomerics CEO Andreas Schatzlein attended a BIA Roundtable Discussion hosted by George Freeman MP, Government Life Sciences Adviser. The meeting will examine "What can France and the UK learn from each other in Life Sciences?".

Nanomerics CSO Appointed to the Engineering and Physical Sciences Research Council's Healthcare Technologies Strategic Advisory Team

EPSRC logoNanomerics CSO Professor Ijeoma F. Uchegbu has been appointed to the EPSRC's Healthcare Technologies Strategic Advisory Team.  Her appointment is with effect from 1st of April 2013.  The EPSRC's Strategic Advisory Teams provide the EPSRC with expert advice on its research and training strategy across its portfolio.

Nanomerics selected as one of UK’s most innovative life science SMEs to attend Bio 2013

BIA logoFour innovative UK life science companies will have the chance to promote their businesses and create new connections after winning the recent UK Trade and Investment (UKTI) Innovation Competition.

As one of the winning companies Nanomerics will showcase their life science technologies to an international audience at the upcoming BIO 2013 Convention in Chicago.  Nanomerics receives up to £1,500 towards flights and accommodation, and one year’s complimentary membership of the BioIndustry Association (BIA).

UCL News reports Nanomerics technology breakthrough

UCLNews

UCL News reports on the development of nano fibres as brain agents for the delivery of drugs across the blood brain barrier. The technology was developed by the team around Nanomerics CSO Prof Uchegbu and provides a new approach to the delivery of peptides to the brain. This technology extends Nanomerics portfolio of technologies that can be applied to it Pharmaceutics Discovery approach to the develpment of novel medicines based on known compounds.

 

Chemical & Engineering News Reports on Nanomerics Nanofibres

 

Chemical & Engineering News reports on Nanomerics' peptide nanofibres technology delivering the analgesic peptide Dalargin to the brain. C&EN logo

Nanofibres Deliver Therapeutic Peptides to the Brain

ACSNano_logo

It is notoriously hard to deliver therapies to the brain, primarily because of the presence of the blood brain barrier. Nanomerics scientists report peptide nanofibers may provide a new approach to deliver medicines to the brain.

Nanomerics CSO wins Royal Pharmaceutical Society's Pharmaceutical Scientist of the Year Award

Ijeoma Uchegbu, Nanomerics' CSO and Professor of Pharmaceutical Nanoscience, at the University College London School of Pharmacy, has won the Pharmaceutical Scientist of the Year Award from the Royal Pharmaceutical Society. The award was given for her work on developing technologies, specifically, the use of Nanomerics' MET systems, for the treatment of brain diseases.

Nanomerics awarded TSB Funding

Submitted by info on Wed, 02/08/2012 - 1:29pm

Molecular Envelope Technology

Nanomerics has successfully won its funding bid to the Technology Strategy Board (TSB) for £1,200,000 towards groundbreaking research aimed at developing a new form of pain relief.

The new drug, the METDoloron peptide pill – based on peptides rather than opioids – avoids the sometimes serious side-effects of opioid-based drugs by targeting different receptors in the brain, and uses an agent which is produced by the body itself to control pain. Peptides are molecules produced by the body which can act as nature’s own ‘drugs’.

The peptide pill utilizes Nanomerics’ Molecular Envelope Technology (MET), to enable the peptides within it – usually broken down by the body in the gut if ingested orally – to be absorbed by the body and provide effective pain relief.

MET Fibrous Hydrogel
MET Fibrous Hydrogel
Subscribe to Nanomerics RSS